• Injectable Growth Hormone Peptides Eptifibatide Raw Steroid Powders CAS 148031-34-9 Manufacturer supply high purity peptide for

Injectable Growth Hormone Peptides Eptifibatide Raw Steroid Powders CAS 148031-34-9 Manufacturer supply high purity peptide for Body Building

stars, based on ( 0 )reviews
$1.00 kilogram
0items available

Injectable Growth Hormone Peptides Eptifibatide Raw Steroid Powders CAS 148031-34-9 Manufacturer supply high purity peptide Eptifibatide for Body Building



We are factory from China.We make peptides and HGH from China 


We can also make capsules, tablets, and liquid drops. Customers brand is accpetable.


Our email is sales@sarms4muscle.com



Basic Info.




Injectable
Growth Hormone
Peptides
Eptifibatide
Raw Steroid Powders
CAS 148031-34-9
Manufacturer
supply high purity peptide
Body Building




 

 

 

Eptifibatide

Sequence: Mpr-Har-Gly-Asp-Trp-Pro-Cys-NH2

Cas No.: 148031-34-9

Molecular Formula: C35H49N11O9S2

Molecular Weight: 831.96

Appearance: White slightly yellwish powder

Specific Rotation[20/D]: -75.0~-95.0°(C=1,1%HAc)

Amino Acids composition: ± 10%

Peptide Purity (By HPLC): >98% by area integration

Related Substance (By HPLC): Total Impurities (%)<2.0%;Largest Single Impurity (%)< 1.0%

Water Content (Karl Fischer): <8.0%

Peptide Content(N determination): >80%

Acetate Content: <15%

IR spectrum: in accordance

Grade : Pharmaceutical Grade

Storage: Closed, below 2 ~ 8ºC preservation

Usage : Platelet glycoprotein receptor antagonist model, the third generation of antiplatelet drugs. For acute coronary syndrome (including unstable angina or non Q wave myocardial infarction) or percutaneous coronary interventional therapy (including angioplasty or atheromatous plaque excision).

 

 

Description:

 

 

 

Eptifibatide (Integrilin, Millennium Pharmaceuticals, also co-promoted by Schering-Plough/Essex), is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class.[1] Eptifibatide is a cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). It belongs to the class of the so-called arginin-glycin-aspartat-mimetics and reversibly binds to platelets. Eptifibatide has a short half-life. The drug is the third inhibitor of GPIIb/IIIa that has found broad acceptance after the specific antibody abciximab and the non-peptide tirofiban entered the global market.

Integrilin is sold in two strengths, globally: vials containing 2 mg/ml (20 mg totally) and 0.75 mg/ml (75 mg totally).

 

 

Application:

 

 

 

Eptifibatide is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary intervention (PCI).

 

 

 

The drug is usually applied together with aspirin or clopidogrel and (low molecular weight or unfractionated) heparin. Additionally, the usual supportive treatment consisting of applications of nitrates, beta-blockers, opioid analgesics and/or benzodiazepines should be employed as indicated. Angiographic evaluation and other intensive diagnostic procedures may be considered a first line task before initiating therapy with eptifibatide.

 

 

 

Human growth hormone:

 

 

 

GHRP-6 5mg/vial GHRP-2 5mg/vial Ipamorelin 5mg/vial Ipamorelin 5mg/vial

CJC-1295 with DAC 2mg/vial CJC-1295 W/O DAC 2mg/vial MT-2 10mg/vial MT-1 10mg/vial

PEG-MGF (IGF 1EC)2mg/vial PEG-MGF 2mg/vial HGH FAG 176-191 5mg/vial FAG 176-195 2mg/vial

Hexarelin 5mg/vial Hexarelin 2mg/vial Thymosin bate 4 2mg/vial Sermorelin 2mg/vial

PT-141 10mg/vial DSIP 5mg/vial DSIP 1mg/vial Selank 5mg/vial

Selank 2mg/vial Oxytocin 2mg/vial Gonadorelin 2mg/vial Triptorelin 100mcg/vial

GHRP 2mg/vial Tesamorelin 2mg/vial BPC 157 5mg/vial Follistatin 1mg/vial

 

 

Indications:

 

 

Eptifibatide is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary intervention (PCI). The drug is usually applied together with aspirin or clopidogrel and (low molecular weight or unfractionated) heparin. Additionally, the usual supportive treatment consisting of applications of nitrates, beta-blockers, opioid analgesics and/or benzodiazepines should be employed as indicated. Angiographic evaluation and other intensive diagnostic procedures may be considered a first line task before initiating therapy with eptifibatide. The drug should exclusively be used in hospitalized patients both because of the serious degree of patients' illness and because of the possible side-effects of eptifibatide.

 

 

Contraindications and precautions:

 

 

1. Thrombocytopenia : The drug is contraindicated in patients with platelet counts of less than 100,000 per l because no clinical experience exists regarding such patients.

 

2. Renal insufficiency : Eptifibatide undergoes renal elimination. In such patients with renal insufficiency where a glycoprotein IIb/IIIa inhibitor is likely to provide benefit, Abciximab (trade name: Reopro) is an alternative medication.

 

3. Current bleeding tendencies or abnormally prolonged coagulation parameters observed within 30 days before starting therapy with eptifibatide is intended.

 

4. Coagulation parameters such as ACT, aPTT, TT, and PT should be followed closely during therapy and afterwards. Allergy to eptifibatide and/or other ingredients. Severe, uncontrolled hypertension.

 

5. Pregnancy : No experience exists. Pregnant patients should be treated only when clearly needed.

 

6. Lactation : No human data exists. Breast-feeding should be avoided during treatment in order to prevent damage to the newborn.

 

7. Geriatric patients : No differences in side effects compared with younger patients have been seen. Nevertheless, geriatric patients should be very closely observed for bleeding and other side-effects.

 

8. Pediatric patients : Eptifibatide is not indicated in patients below 18 years of age, because no experience exists

 


Recent Reviews
+